Mepolizumab for the treatment of severe eosinophilic asthma

American Journal of Health-System Pharmacy

Volumn 74, Issue 13, 2017, Pages 963-969

  Poulakos, Mara N ^a   Cargill, Shawna M ^b   Waineo, Melissa F ^c   Wolford, Allen L ^c  

^a PALM BEACH ATLANTIC UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antiasthmatic agents; Asthma; Eosinophils; Interleukin 5; Mepolizumab; Monoclonal antibodies

Indexed keywords

MEPOLIZUMAB; INTERLEUKIN 5; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADVERSE OUTCOME; ASTHMA; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL COUNT; EOSINOPHILIA; HUMAN; MAINTENANCE THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); EOSINOPHIL; IMMUNOLOGY; METABOLISM; PROCEDURES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CLINICAL TRIALS AS TOPIC; EOSINOPHILS; HUMANS; INTERLEUKIN-5; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85021429836     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp160291     Document Type: Review

References (28)

1. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007; 120:S94-138.
2. Kelly H, Sorkness CA. Asthma. Chapt. 15. In: DiPiro JT, Talbert RL, Yee GC et al., eds. Pharmacotherapy: A pathophysiologic approach. 9th ed. New York: McGraw-Hill; 2014.
3. Centers for Disease Control and Prevention. Asthma. www.cdc.gov/asthma/(accessed 2015 Dec 20).
4. Third Expert Panel on the Management of Asthma. Global strategy for asthma management and prevention, Global Initiative for Asthma (GINA) 2015, www.ginasthma.org/(accessed 2015 Dec 20).
5. Nucala (mepolizumab) package insert. Research Triangle Park, NC: GlaxoSmithKline. 2015.
6. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 2006; 368:804-13.
7. Walford HH, Doherty TA. Diagnosis and management of eosinophilic asthma: A US perspective. J Asthma Allergy. 2014; 7:53-65.
8. Chung KF, Wenzel SE, Brozek JL et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014; 43:343-73.
9. Food and Drug Administration. FDA advisory committee meeting briefing document: Nucala (mepolizumab) for treatment of patients with severe asthma with eosinophilic inflammation (May 7, 2015). www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM450248.pdf (accessed 2016 Jan 5).
10. Cinquair (reslizumab) package insert. Frazer, PA: Teva Pharmaceuticals. 2016
11. Castro M, Mathur S, Hargreave F et al. Reslizumab for poorly controlled, eosinophilic asthma: A randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011; 184:1125-32.
12. Busse WW, Katial R, Gossage D et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor a antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol. 2010; 125:1237-44.
13. Laviolette M, Gossage DL, Gauvreau G et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013; 132:1086-96.
14. Flood-Page P, Menzies-Gow A, Phipps S et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest. 2003; 112:1029-36.
15. Mepolizumab [monograph]. In: Lexicomp Online [online database]. Hudson, OH: Lexi-Comp (accessed 2016 Dec 27).
16. Corren J. Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discov Med. 2012; 13:305-12.
17. Humbert M, Corrigan CJ, Kimmitt P et al. Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med. 1997; 156:704-8.
18. Kips JC, OConnor BJ, Langley SJ et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: A pilot study. Am J Respir Crit Care Med. 2003; 167:1655-9.
19. Haldar PH, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009; 360:973-84.
20. Bel EH, Wenzel SE, Thompson PJ et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014; 371:1189-97.
21. Nair P, Pizzichini MM, Kjarsgaard M et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009; 360:985-93.
22. Flood-Page P, Swenson C, Faiferman I et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007; 176:1062-71.
23. Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (DREAM): A multicenter, double-blind, placebo-controlled trial. Lancet. 2012; 380:651-9.
24. Menzies-Gow A, Flood-Page P, Sehme R et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol. 2003; 111:714-9.
25. Flood-Page P, Menzies-Gow AN, Kay AB et al. Eosinophils role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003; 167:199-204.
26. Ortega HG, Liu MC, Pavord ID et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014; 371:1198-207.
27. Cisternas MG, Blanc PD, Yen IH et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol. 2003; 111:1212-8.
28. Institute for Clinical and Economic Review. Mepolizumab (Nucala, GlaxoSmithKline plc.) for the treatment of severe asthma with eosinophilia: effectiveness, value, and value-based price bench marks (2016). www.icer-review.org/wp-content/uploads/2016/03/CTAF-Mepolizumab-Final-Report-031416.pdf (accessed 2016 Jan 20).